Pheochromocytoma epidemiology and demographics
|
Pheochromocytoma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Pheochromocytoma epidemiology and demographics On the Web |
|
American Roentgen Ray Society Images of Pheochromocytoma epidemiology and demographics |
|
Risk calculators and risk factors for Pheochromocytoma epidemiology and demographics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ahmad Al Maradni, M.D. [2]Mohammed Abdelwahed M.D[3]
Overview
The incidence of pheochromocytoma ranges from a low of 0.2 per 100,000 persons to a high of 0.8 per 100,000 persons. The average age at diagnosis is 24.9 years in hereditary cases and 43.9 years in sporadic cases with men and women equally affected.[1]
Epidemiology and Demographics
Incidence
In the USA, the incidence of pheochromocytoma ranges from a low of 0.2 per 100,000 persons to a high of 0.8 per 100,000 persons [1] and 500 to 1600 cases in the United States per year [2] but autopsy series discovered numbers higher that those of prevalence rates. 10% of pheochromocytomas are discovered by chance. null 22
Pheochromocytomas occur all races but less in black. Approximately 10% occur in children. Fifty percent of pheochromocytomas in children are solitary intra-adrenal lesions, 25% are present bilaterally, and 25% are extra-adrenal.
Most catecholamine-secreting tumors are sporadic. However, 30% of patients got the tumor as a part of familial disease, the catecholamine-secreting tumors are more likely to be bilateral.[3]
Age
The peak incidence of pheochromocytoma occurs in third to fifth decades of life; the average age at diagnosis is 24.9 years in hereditary cases and 43.9 years in sporadic cases.[1]. Hereditary tumors present at a younger age than sporadic.
Gender
Men and women are equally affected by pheochromocytoma.[1]
References
- ↑ 1.0 1.1 1.2 1.3 National Cancer Institute. Physician Data Query Database 2015. National Cancer Institute. Physician Data Query Database 2015. http://www.cancer.gov/types/pheochromocytoma/hp/pheochromocytoma-treatment-pdq#link/_25_toc
- ↑ Chen H, Sippel RS, O'Dorisio MS, Vinik AI, Lloyd RV, Pacak K; et al. (2010). "The North American Neuroendocrine Tumor Society consensus guideline for the diagnosis and management of neuroendocrine tumors: pheochromocytoma, paraganglioma, and medullary thyroid cancer". Pancreas. 39 (6): 775–83. doi:10.1097/MPA.0b013e3181ebb4f0. PMC 3419007. PMID 20664475.
- ↑ Pamporaki C, Hamplova B, Peitzsch M, Prejbisz A, Beuschlein F, Timmers HJLM; et al. (2017). "Characteristics of Pediatric vs Adult Pheochromocytomas and Paragangliomas". J Clin Endocrinol Metab. 102 (4): 1122–1132. doi:10.1210/jc.2016-3829. PMID 28324046.